A5018861007- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
- Cancer Mechanisms and Therapy
- Chromatin Remodeling and Cancer
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Mechanisms of cancer metastasis
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Acute Myeloid Leukemia Research
- Ethics in Clinical Research
- Brain Metastases and Treatment
- Synthesis and biological activity
- Ovarian cancer diagnosis and treatment
University of California, Los Angeles
2017-2025
UCLA Jonsson Comprehensive Cancer Center
2023-2025
UCLA Health
2020-2025
APLA Health
2024
Southern California Clinical and Translational Science Institute
2019
The US Oncology Network
2019
Columbia University
2019
Zhongshan Hospital
2019
Fudan University
2019
University of California System
2017
Molecular modifiers of KRASG12C inhibitor (KRASG12Ci) efficacy in advanced KRASG12C-mutant NSCLC are poorly defined. In a large unbiased clinicogenomic analysis 424 patients with non-small cell lung cancer (NSCLC), we identified and validated coalterations KEAP1, SMARCA4, CDKN2A as major independent determinants inferior clinical outcomes KRASG12Ci monotherapy. Collectively, comutations these three tumor suppressor genes segregated into distinct prognostic subgroups captured ∼50% those early...
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) CTLA4 inhibitors and PD-1 or PD-L1 (hereafter, PD-(L)1 inhibitors) is associated higher rates of anti-tumour activity immune-related toxicities, when compared treatment alone. However, there are currently no validated biomarkers to identify which will benefit from ICB1,2. Here we show that NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical ICB...
Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.
Abstract ADCs have revolutionized the therapeutic landscape in oncology. Three are US FDA-approved MBC: sacituzumab govitecan (SG), trastuzumab deruxtecan (T-DXd) and emtansine (T-DM1), with many others development. Despite these advances, ADC resistance mechanisms remain unknown. To discern biomarkers of resistance, we evaluated genomic transcriptomic differences MBC before after treatment (tx). We analyzed next-generation sequencing (NGS) data from patients (pts) Tempus Database that...
8517 Background: TALA exhibits cytotoxic effects by inhibiting poly (ADP-ribose) polymerase (PARP) proteins 1 and 2 in addition to “trapping” PARP on DNA. TMZ has been shown increase antitumor response when combined with SCLC models (Wainberg AACR 2016). plus as second-line therapy for ES-SCLC may improve disease-related outcomes. Methods: This is a phase 2, open-label, single-arm study of the safety efficacy patients ES-SCLC, relapsed or refractory first-line platinum-based regimen....
Health care research increasingly relies on assessment of data extracted from electronic medical records (EMRs). Clinical trial adverse event (AE) logs and patient-reported outcomes (PROs) are sources often available in the context specific projects. The aim this study was to evaluate extent concordance these sources.Patients enrolled clinical trials or receiving standard treatment for lung cancer (n = 62) completed validated questionnaires physical psychological symptoms at up three points....
Abstract Purpose: Although PD-(L)1 inhibitors have shown efficacy in advanced/metastatic non–small cell lung cancer (NSCLC), many patients do not respond to this treatment and more effective combinations with acceptable toxicities are needed. To assess the potential benefit of combining localized innate immune stimulation checkpoint blockade, TLR9 agonist DV281 was combined nivolumab a phase Ib study. Patients Methods: after one or two prior lines systemic therapy were enrolled...
Abstract Background Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not consistently indicative of response. Other markers within the tumor microenvironment (TIME) may better reflect response and/or resistance mechanisms, but an understanding how TIMEs differ between stage III IV NSCLC has explored. Methods...
The thinking underlying people's positions on complex issues is often of limited scope or complexity, yet changing minds notoriously difficult. We investigated the Deferred Action for Childhood Arrivals program. Rather than seek to influence their by engaging them in considering alternative views, we effectiveness discourse asking explore limitations, inconsistencies, and unresolved with respect own positions. Might doing so enrich about issue? This hypothesis was disconfirmed, showing...
3077 Background: While targeted DNA-seq can detect clinically actionable fusions in tumor tissue samples, technical and analytical challenges may give rise to false negatives. RNA-based, whole-exome sequencing provides a complementary method for fusion detection, improve the identification of variants. In this study, we quantify benefit using large, real-world clinical dataset assess detected from RNA conjunction with DNA profiling. Methods: Using Tempus Research Database, retrospectively...
9014 Background: Despite the significant antitumor activity of pembrolizumab in non-small cell lung cancer (NSCLC), clinical benefit has been less frequently observed patients whose tumors harbor epidermal growth factor receptor (EGFR) mutations compared to EGFR wild-type patients. Our single center experience on KEYNOTE-001 trial suggested that pembrolizumab-treated EGFR-mutant patients, who were tyrosine kinase inhibitor (TKI) naïve, had superior outcomes those previously treated with a...